Get the Stockscreener App
9.46
2.47%
-0.24
Tevogen Bio Holdings Inc stock is traded at $9.46, with a volume of 13,177.
It is down -2.47% in the last 24 hours and up +6.53% over the past month.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.
See More
Previous Close:
$9.70
Open:
$10.1
24h Volume:
13,177
Relative Volume:
0.44
Market Cap:
$39.91M
Revenue:
-
Net Income/Loss:
$-26.28M
P/E Ratio:
-2.2056
EPS:
-4.2891
Net Cash Flow:
$-12.39M
1W Performance:
-18.94%
1M Performance:
+6.53%
6M Performance:
-50.30%
1Y Performance:
-84.23%
1-Day Range:
$9.46
$10.34
1-Week Range:
$9.15
$12.03
52-Week Range:
$4.1353
$71.00
Tevogen Bio Holdings Inc Stock (TVGN) Company Profile
Name
Tevogen Bio Holdings Inc
Sector
Industry
Phone
646-807-8832
Address
15 INDEPENDENCE BOULEVARD, SUITE #210, WARREN
Compare TVGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVGN
Tevogen Bio Holdings Inc
|
9.46 | 39.91M | 0 | -26.28M | -12.39M | -4.2891 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tevogen Bio Holdings Inc Stock (TVGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-26 | Downgrade | D. Boral Capital | Buy → Hold |
| Mar-04-25 | Initiated | D. Boral Capital | Buy |
Tevogen Bio Holdings Inc Stock (TVGN) Latest News
Tevogen Bio Holdings Inc (TVGNW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tevogen Bio Holdings Inc (TVGNW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tevogen Bio Holdings Inc (TVGNW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tevogen Bio Holdings Inc (TVGNW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tevogen Bio Holdings Inc (TVGNW) Institutional Confidence - TradingKey
Tevogen Bio Holdings Inc (TVGNW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tevogen Bio Holdings Inc (TVGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tevogen Bio Holdings Inc (TVGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tevogen Bio Holdings Inc (TVGN) Institutional Confidence - TradingKey
Tevogen Bio Holdings Inc (TVGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tevogen Bio Holdings Inc (TVGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tevogen Bio Holdings Inc (TVGNW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tevogen Bio Holdings Inc (TVGNW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tevogen Bio Holdings Inc (TVGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tevogen Bio Holdings Inc (TVGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tevogen Bio Holdings Inc (TVGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tevogen Bio Holdings Inc. Q4 2025 Earnings: Narrower Loss Beats Expectations as Development Progress ContinuesROIC Trend Report - newsline.com
Tevogen Bio (TVGN) registers 375,000 shares for resale by Patel Family - Stock Titan
Tevogen Bio Q4 2025 Earnings: EPS Surprise Beat Amid Ongoing Operational ChallengesGeographic Revenue Trends - newsline.com
Tevogen Bio Warrants (TVGNW) Stall at $0.04 as Trading Remains FlatLow Vol ETF - newsline.com
Tevogen Announces Formation of a Healthcare Services Initiative - Taiwan News
Number of shareholders of Tevogen Bio Holdings Inc. – NASDAQ:TVGNW - TradingView
Tevogen Bio Holdings Inc. Announces William Keane as Interim Head of New Healthcare Services Initiative, Exploring MSO and CRO Acquisitions - Quiver Quantitative
Tevogen weighs $100M in potential MSO, CRO revenue with new unit - Stock Titan
TVGN Q4 2025 Earnings: Narrowed Loss Per Share Exceeds Expectations, Shares RisePost-Earnings Reaction - newsline.com
Tevogen Bio Q4 2025 Earnings: EPS Surprise Beats Estimates Despite No Revenue, Shares RiseAnalyst Consensus Shift - newsline.com
TVGN Q4 2025 Earnings: Narrowed Loss Beats Expectations as Stock SurgesSlow Growth Warning - newsline.com
TEVOGEN BIO HOLDINGS INC (TVGN) Stock Chart - ChartMill
Why Is Tevogen Bio Holdings Inc. (TVGNW) Stock Down Today? - Meyka
Tevogen Bio Holdings Inc. (TVGN) Q4 2025 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline AdvancesRevenue Beat Analysis - newsline.com
Tevogen Bio (TVGN) Dips 1.62% as Shares Approach Critical Support at $7.51Support Level Bounce - newsline.com
Tevogen Shares Drop After $100 Million Revenue Target; Deal Risk Eyed - Bez Kabli
TVGN News | TEVOGEN BIO HOLDINGS INC (NASDAQ:TVGN) - ChartMill
Tevogen Bio Holdings Inc. Outlines Strategic Acquisition Initiatives Aiming for $100 Million in Annual Revenue - Quiver Quantitative
Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 ... - Caledonian Record
Tevogen outlines biotech, AI and healthcare services vision - Stock Titan
Tevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue - FinanzNachrichten.de
Tevogen Bio Warrant (TVGNW) Holds at $0.04 with Modest UptickDividend Growth Stocks - newsline.com
Tevogen Bio Holdings (TVGN) Slides 10.5% as Selling Pressure IntensifiesMomentum Breakout Ideas - newsline.com
Tevogen Bio Warrants Hold Flat at $0.04 as Support and Resistance ConvergePrice Surge Stocks - The Legal Advocate
Tevogen Bio Holdings Q4 2025 Earnings: Narrower-than-Expected Loss Fails to Lift SharesInstitutional Grade Picks - Newser
TVGN Q4 2025 Earnings: Narrower-Than-Expected Loss but No Revenue Growth Keeps Stock Under PressureConsensus Beat Rate - The Legal Advocate
Tevogen Bio Holdings Warrant (TVGNW) Stalls at $0.04 as Trading Remains FlatMACD Signal Stocks - Newser
Tevogen Bio Holdings Inc. (TVGN) Stock: Jumps 11.74% on Potential Healthcare Expansion Deal - parameter.io
Tevogen Also Considering Other Transactions With a Focus on Life Sciences and Healthcare-Related Businesses - Moomoo
Tevogen Bio Holdings Inc. Signs Non-Binding Letter of Intent to Explore Strategic Healthcare Transaction - Quiver Quantitative
Tevogen explores MSO deal that could pave path to $100M - Stock Titan
Tevogen Bio Holdings Company Profile & Introduction - Moomoo
Letter to Shareholders from CEO Dr. Ryan Saadi - Sahm
TVGN Shares Updates on Operational Improvements and Strategic Go - GuruFocus
Tevogen reports reduced operating losses in 2025 and Q1 2026 By Investing.com - Investing.com Nigeria
Tevogen Bio Holdings Inc Stock (TVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):